Get the Stockscreener App
693.46
0.47%
3.21
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Mckesson Corporation stock is traded at $693.46, with a volume of 1.96M.
It is up +0.47% in the last 24 hours and up +3.23% over the past month.
McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
See More
Previous Close:
$690.25
Open:
$712.5
24h Volume:
1.96M
Relative Volume:
2.00
Market Cap:
$88.78B
Revenue:
$344.58B
Net Income/Loss:
$2.83B
P/E Ratio:
31.75
EPS:
21.84
Net Cash Flow:
$1.63B
1W Performance:
-2.11%
1M Performance:
+3.23%
6M Performance:
+13.13%
1Y Performance:
+24.92%
1-Day Range:
$682.43
$721.64
1-Week Range:
$682.43
$728.48
52-Week Range:
$464.42
$728.48
Mckesson Corporation Stock (MCK) Company Profile
Name
Mckesson Corporation
Sector
Industry
Phone
972-446-4800
Address
6555 STATE HIGHWAY 161, IRVING, TX
Compare MCK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCK
Mckesson Corporation
|
693.46 | 88.78B | 344.58B | 2.83B | 1.63B | 21.84 |
|
COR
Cencora Inc
|
283.00 | 56.59B | 310.23B | 1.69B | 3.58B | 8.62 |
|
CAH
Cardinal Health Inc
|
148.22 | 35.69B | 222.29B | 1.56B | 2.44B | 6.41 |
|
HSIC
Henry Schein Inc
|
68.64 | 7.95B | 12.50B | 314.00M | 421.00M | 2.44 |
|
OMI
Owens Minor Inc
|
7.01 | 580.18M | 10.42B | -38.77M | 323.54M | -0.51 |
Mckesson Corporation Stock (MCK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-24 | Resumed | Mizuho | Neutral |
| Nov-07-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-05-24 | Reiterated | Leerink Partners | Outperform |
| Aug-08-24 | Reiterated | Mizuho | Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Overweight |
| Jul-06-22 | Downgrade | Argus | Buy → Hold |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Feb-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-02-21 | Reiterated | Barclays | Overweight |
| Nov-02-21 | Reiterated | BofA Securities | Buy |
| Nov-02-21 | Reiterated | Evercore ISI | Outperform |
| Nov-02-21 | Reiterated | Jefferies | Buy |
| Mar-30-21 | Upgrade | Argus | Hold → Buy |
| Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-04-20 | Upgrade | Deutsche Bank | Hold → Buy |
| May-22-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| May-15-20 | Upgrade | UBS | Neutral → Buy |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Mar-18-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-13-20 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-10-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Aug-05-19 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jul-22-19 | Initiated | Guggenheim | Neutral |
| Jan-17-19 | Initiated | UBS | Neutral |
| Oct-26-18 | Reiterated | Barclays | Equal Weight |
| Jul-20-18 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-29-18 | Reiterated | Leerink Partners | Mkt Perform |
| Mar-08-18 | Initiated | Barclays | Equal Weight |
| Feb-27-18 | Resumed | BofA/Merrill | Buy |
| Feb-02-18 | Reiterated | Mizuho | Neutral |
| Jan-24-18 | Upgrade | Jefferies | Hold → Buy |
View All
Mckesson Corporation Stock (MCK) Latest News
McKesson to Spin Off Medical-Surgical Company - MSN
Jefferies raises McKesson stock target to $800; maintains buy By Investing.com - Investing.com Nigeria
McKesson’s Earnings Call: Record Growth Amid Challenges - TipRanks
McKesson (MCK) Stock Moves on Q4 Fiscal 2025 Earnings Report - GuruFocus
Health Care Down Sharply on Drug-Demand Fears -- Health Care Roundup - marketscreener.com
Why McKesson Stock Bumped Modestly Higher Today - Yahoo Finance
McKesson Set To Spin Off Med-Surg Solutions Unit - Finimize
McKesson to spin-off surgical supplies business, focus on oncology - The Business Journals
McKesson's Fiscal Q4 'More Loaded Than Normal' Amid Spin-Off News, UBS Says - marketscreener.com
Jefferies raises McKesson stock target to $800; maintains buy - Investing.com
McKesson Posts 16% Annual Sales Increase; Will Divest Medical-Surgical Unit - Modern Distribution Management
McKesson’s Broad-Based Growth Is Fueled by GLP-1s, Customer Win, and a Growing Specialty Portfolio - Morningstar
McKesson: Spin-Off Of Medical-Surgical Solutions Is A Positive, Strong Buy (NYSE:MCK) - Seeking Alpha
McKesson to spin off medical-surgical segment - DOTmed
McKesson Spins Off Unit To Laser In On Core Drugs - Finimize
Evercore ISI Adjusts Price Target on McKesson to $760 From $740, Maintains Outperform Rating - marketscreener.com
Baird Adjusts Price Target on McKesson to $796 From $765, Maintains Outperform Rating - marketscreener.com
Deutsche Bank Adjusts Price Target on McKesson to $740 From $692 - marketscreener.com
McKesson's (NYSE:MCK) investors will be pleased with their enviable 452% return over the last five years - Yahoo Finance
McKesson Corporation (NYSE:MCK) Q4 2025 Earnings Call Transcript - MSN
McKesson price target raised to $800 from $755 at BofA - TipRanks
McKesson Reports Strong Earnings and Strategic Plans - TipRanks
McKesson projects $36.75-$37.55 EPS for fiscal 2026 with oncology and biopharma growth - MSN
McKesson Corporation (NYSE:MCK) Q1 2025 Financial Results OverviewNews and Statistics - IndexBox
MCKESSON CORP SEC 10-K Report - TradingView
McKesson’s Transfer Pricing Suit Seeks to Bring Back Tax Breaks - news.bloombergtax.com
McKesson Corp (MCK) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... - Yahoo Finance
McKesson Corp (MCK) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic Growth Initiatives - GuruFocus
McKesson: Fiscal Q4 Earnings Snapshot - CT Insider
McKesson (MCK) Reports Strong Q4 2025 Performance, Plans Strategic Spin-Off - GuruFocus
McKesson Corporation 2025 Q4ResultsEarnings Call Presentation (NYSE:MCK) - Seeking Alpha
Earnings call transcript: McKesson Q3 2025 beats EPS forecasts, stock dips - Investing.com
Here's What Key Metrics Tell Us About McKesson (MCK) Q4 Earnings - Yahoo Finance
McKesson (NYSE:MCK) Misses Q1 Revenue Estimates - Yahoo Finance
McKesson Q4 & FY25 slides: Revenue up 16%, projects 11-14% EPS growth for FY26 - Investing.com India
McKesson to spin off surgical supplies unit, forecasts strong annual profit - marketscreener.com
McKesson (MCK) Tops Q4 Earnings Estimates - Yahoo Finance
McKesson stock up on encouraging 2026 profit guidance - MSN
McKesson to separate Medical-Surgical Solutions segment as independent company - TipRanks
McKesson shares rise as Q4 earnings top estimates By Investing.com - Investing.com South Africa
McKesson (MCK) Offers Positive Earnings Guidance for Fiscal 2026 | MCK Stock News - GuruFocus
McKesson shares rise as Q4 earnings top estimates - Investing.com Australia
McKesson (MCK) Plans Separation of Medical-Surgical Segment into NewCo | MCK Stock News - GuruFocus
McKesson (MCK) Surpasses Earnings Expectations Despite Lower Revenue in Q4 | MCK Stock News - GuruFocus
McKesson Corp Q4 Earnings: EPS Surpasses Estimates at $10.01, Revenue Falls Short at $90.8 Billion - GuruFocus
McKesson earnings beat by $0.31, revenue fell short of estimates - Investing.com India
McKesson Reports Fiscal 2025 Fourth Quarter and Full Year Results and Provides Fiscal 2026 Guidance; Announces Intent to Separate Medical-Surgical Solutions - Yahoo Finance
Jim Cramer on McKesson Corporation (MCK): ‘Defying Doubters as a Middleman Money Machine’ - MSN
How To Earn $500 A Month From McKesson Stock Ahead Of Q4 Earnings - Benzinga
McKesson, Monster Beverage, Expedia set to report earnings Thursday - Investing.com
Stan Wong's Past Picks: Restaurant Brands International, Home Depot & McKesson - BNN Bloomberg
Mckesson Corporation Stock (MCK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):